These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1662477)

  • 1. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
    Klockgether T; Turski L; Honoré T; Zhang ZM; Gash DM; Kurlan R; Greenamyre JT
    Ann Neurol; 1991 Nov; 30(5):717-23. PubMed ID: 1662477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists.
    Maj J; Rogóz Z; Skuza G; Jaros T
    Pol J Pharmacol; 1995; 47(4):269-77. PubMed ID: 8616504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia.
    Tachibana Y; Iwamuro H; Kita H; Takada M; Nambu A
    Eur J Neurosci; 2011 Nov; 34(9):1470-84. PubMed ID: 22034978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNQX but not NBQX prevents expression of amphetamine-induced place preference conditioning: a role for the glycine site of the NMDA receptor, but not AMPA receptors.
    Mead AN; Stephens DN
    J Pharmacol Exp Ther; 1999 Jul; 290(1):9-15. PubMed ID: 10381753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed antagonism of AMPA/kainate receptors reduces long-term functional deficits resulting from spinal cord trauma.
    Wrathall JR; Teng YD; Marriott R
    Exp Neurol; 1997 Jun; 145(2 Pt 1):565-73. PubMed ID: 9217092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
    Löschmann PA; Kunow M; Wachtel H
    J Neural Transm Suppl; 1992; 38():55-64. PubMed ID: 1491248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
    Löschmann PA; Lange KW; Kunow M; Rettig KJ; Jähnig P; Honoré T; Turski L; Wachtel H; Jenner P; Marsden CD
    J Neural Transm Park Dis Dement Sect; 1991; 3(3):203-13. PubMed ID: 1835581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
    Luquin MR; Obeso JA; Laguna J; Guillén J; Martínez-Lage JM
    Eur J Pharmacol; 1993 Apr; 235(2-3):297-300. PubMed ID: 7685291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
    O'Neill MJ; Murray TK; Whalley K; Ward MA; Hicks CA; Woodhouse S; Osborne DJ; Skolnick P
    Eur J Pharmacol; 2004 Feb; 486(2):163-74. PubMed ID: 14975705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
    Wachtel H; Kunow M; Löschmann PA
    Neurosci Lett; 1992 Aug; 142(2):179-82. PubMed ID: 1280793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of operant oral self-administration of ethanol, sucrose, and saccharin by the AMPA/kainate antagonist, NBQX, but not the AMPA antagonist, GYKI 52466.
    Stephens DN; Brown G
    Alcohol Clin Exp Res; 1999 Dec; 23(12):1914-20. PubMed ID: 10630610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic excitatory amino acid receptor antagonists of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and of the N-methyl-D-aspartate (NMDA) receptor relieve mechanical hypersensitivity after transient spinal cord ischemia in rats.
    Xu XJ; Hao JX; Seiger A; Wiesenfeld-Hallin Z
    J Pharmacol Exp Ther; 1993 Oct; 267(1):140-4. PubMed ID: 8229741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the AMPA-receptor antagonist, NBQX, on neuron loss in dentate hilus of the hippocampal formation after 8, 10, or 12 min of cerebral ischemia in the rat.
    Hu P; Diemer NH; Bruhn T; Johansen FF
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):147-52. PubMed ID: 9040493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.